Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population

Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population

Abstract Pantoprazole is a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease, a condition that disproportionately affects children with obesity. Appropriately dosing pantoprazole in children with obesity requires understanding the body size metric that best guides...

Full description

Saved in:
Bibliographic Details
Main Authors: Elizabeth J. Thompson, Angela Jeong, Victória E. Helfer, Valentina Shakhnovich, Andrea Edginton, Stephen J. Balevic, Laura P. James, David N. Collier, Ravinder Anand, Daniel Gonzalez, the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
Format: Article
Language:English
Published: Wiley 2024-08-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.13167
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items